XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total
Balances, at Beginning of period at Dec. 31, 2020 $ 3,000 $ 371,228,000   $ (33,094,000) $ 338,137,000
Balances, at Beginning of period (in shares) at Dec. 31, 2020 39,308,238        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Vesting of restricted stock awards (in shares) 6,990        
Vesting of early exercised stock options   31,000     31,000
Stock-based compensation expense $ 26,901 3,144,000     3,144,000
Employee stock purchase plan expense   64,000     64,000
Net unrealized loss on marketable securities     $ (13,000)   (13,000)
Net loss       (15,339,000) (15,339,000)
Balances, at End of period at Mar. 31, 2021 $ 3,000 374,467,000 (13,000) (48,433,000) 326,024,000
Balances, at End of period (in shares) at Mar. 31, 2021 39,342,129        
Balances, at Beginning of period at Dec. 31, 2021 $ 3,000 388,904,000 (149,000) (104,190,000) $ 284,568,000
Balances, at Beginning of period (in shares) at Dec. 31, 2021 39,797,263        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Vesting of restricted stock awards (in shares) 49,318       49,318
Vesting of early exercised stock options   31,000     $ 31,000
Vesting of early exercised stock options (in shares) 6,989       95,916
Exercise of stock options   33,000     $ 33,000
Exercise of stock options (in shares) 15,755       22,744
Stock-based compensation expense   4,874,000     $ 4,874,000
Employee stock purchase plan expense   91,000     91,000
Net unrealized loss on marketable securities     (1,477,000)   (1,477,000)
Net loss       (23,030,000) (23,030,000)
Balances, at End of period at Mar. 31, 2022 $ 3,000 $ 393,933,000 $ (1,626,000) $ (127,220,000) $ 265,090,000
Balances, at End of period (in shares) at Mar. 31, 2022 39,869,325